WO2001051660A3 - Method and kit for diagnosis of neoplastic transformation - Google Patents

Method and kit for diagnosis of neoplastic transformation Download PDF

Info

Publication number
WO2001051660A3
WO2001051660A3 PCT/IB2001/000088 IB0100088W WO0151660A3 WO 2001051660 A3 WO2001051660 A3 WO 2001051660A3 IB 0100088 W IB0100088 W IB 0100088W WO 0151660 A3 WO0151660 A3 WO 0151660A3
Authority
WO
WIPO (PCT)
Prior art keywords
cox
neoplastic transformation
sample
diagnosis
kit
Prior art date
Application number
PCT/IB2001/000088
Other languages
French (fr)
Other versions
WO2001051660A2 (en
Inventor
Linda A Kowalski
Original Assignee
Vera Genics Ltd
Linda A Kowalski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vera Genics Ltd, Linda A Kowalski filed Critical Vera Genics Ltd
Priority to AU25433/01A priority Critical patent/AU2543301A/en
Publication of WO2001051660A2 publication Critical patent/WO2001051660A2/en
Publication of WO2001051660A3 publication Critical patent/WO2001051660A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention discloses a method and assay kit for the diagnosis of neoplastic transformation in a cell sample, tissue sample, or bodily fluid sample of a patient. Specifically, the detection of cyclooxygenase-1 (COX-1) and/or cyclooxygenase-2 (COX-2) expression and/or biological activity, particularly in conjunction with the detection of the presence of an oncogenic virus, is used as an indicator of neoplastic transformation or a potential for neoplastic transformation in a sample. The invention also includes a method for evaluating the carcinogenicity of a compound by evaluating COX-1 and/or COX-2 expression and/or biological activity in a test cell before and after contact with a putative carcinogen. Diagnostic assay kits suitable for use with the present methods are also disclosed.
PCT/IB2001/000088 2000-01-14 2001-01-12 Method and kit for diagnosis of neoplastic transformation WO2001051660A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU25433/01A AU2543301A (en) 2000-01-14 2001-01-12 Method and kit for diagnosis of neoplastic transformation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17614700P 2000-01-14 2000-01-14
US60/176,147 2000-01-14
US50235500A 2000-02-11 2000-02-11
US09/502,355 2000-02-11

Publications (2)

Publication Number Publication Date
WO2001051660A2 WO2001051660A2 (en) 2001-07-19
WO2001051660A3 true WO2001051660A3 (en) 2002-03-14

Family

ID=26871924

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/000088 WO2001051660A2 (en) 2000-01-14 2001-01-12 Method and kit for diagnosis of neoplastic transformation

Country Status (2)

Country Link
AU (1) AU2543301A (en)
WO (1) WO2001051660A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015146210A (en) * 2013-03-28 2017-05-03 Сентр Оспиталье Юниверситер Де Монпелье METHOD FOR DETERMINING SENSITIVITY TO RADIOACTIVE IRRADIATION
CN106290866A (en) * 2016-08-16 2017-01-04 海南大学 The indirect ELISA detection method of bovine papilloma virus 13 type antibody
CN111876528A (en) * 2020-08-13 2020-11-03 海南大学 PCR kit of bovine papilloma virus oncogene E5 and establishment method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037235A1 (en) * 1997-02-24 1998-08-27 Cornell Research Foundation, Inc. Method of screening agents as candidates for drugs or sources of drugs
WO1998041864A1 (en) * 1997-03-18 1998-09-24 Locus Genex Oy Diagnosis of early gastric cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037235A1 (en) * 1997-02-24 1998-08-27 Cornell Research Foundation, Inc. Method of screening agents as candidates for drugs or sources of drugs
WO1998041864A1 (en) * 1997-03-18 1998-09-24 Locus Genex Oy Diagnosis of early gastric cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LEE C-Y G ET AL: "STUDIES OF A TUMOR-ASSOCIATED ANTIGEN COX-1 RECOGNIZED BY A MONOCLONAL ANTIBODY", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 35, no. 1, 1992, pages 19 - 26, XP001015671, ISSN: 0340-7004 *
LEE G ET AL: "Clinical evaluations of a new ovarian cervical cancer marker COX-1.", CLINICAL CHEMISTRY, vol. 43, no. 6 PART 2, 1997, 49th Annual Meeting of the American Association for Clinical Chemistry;Atlanta, Georgia, USA; July 20-24, 1997, pages S227, XP001015676, ISSN: 0009-9147 *
SHEEHAN KATHERINE M ET AL: "THE RELATIONSHIP BETWEEN CYCLOOXYGENASE-2 EXPRESSION AND COLORECTAL CANCER.", JAMA (JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION), vol. 282, no. 13, 6 October 1999 (1999-10-06), pages 1254 - 1257, XP001015677, ISSN: 0098-7484 *

Also Published As

Publication number Publication date
AU2543301A (en) 2001-07-24
WO2001051660A2 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
CA2351796A1 (en) Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
AR037546A1 (en) REAGENT COMPOSITIONS OF STABILIZED NITRITE TETRAZOL AND METHODS FOR USE
MXPA06003765A (en) Diagnostic test device and method of using same.
EP1266608A3 (en) Biological fluid sampling and analyte measurement devices and methods
BR0109125A (en) Medical diagnostic system
WO2008132620A3 (en) Lateral flow device for attachment to an absorbent article
NO20030251L (en) Method of differentiating between biological states based on hidden patterns from biological data
WO2000040749A3 (en) Method for the detection of gene transcripts in blood and uses thereof
WO2003008933A3 (en) Test strip for a lateral flow assay
ATE289685T1 (en) METHOD FOR DETECTING CARCINOMAS IN SOLUBILIZED CERVICAL BODY SAMPLES
RU2002113638A (en) METHOD, DEVICE, SYSTEM, KIT FOR CARRYING OUT MONITORING OF CONCENTRATION OF AN ANALYSISED SUBSTANCE, METHOD OF CARRYING OUT MONITORING OF GLUCOSE CONCENTRATION
WO2006091911A3 (en) Noninvasive analyzer sample probe interface method and apparatus
AR037544A1 (en) REAGENT COMPOSITIONS OF TETRAZOLIO-FENACINA STABILIZED AND METHODS FOR USE
JPWO2008152980A1 (en) Container for mixing biological sample and reagent and method for mixing biological sample and reagent
WO2001055719A3 (en) Diagnostic kit for detecting creatine levels
Capozza et al. A longitudinal observational study in two cats naturally-infected with hepadnavirus
WO2006122791A3 (en) Tirc7 as marker for detecting early immune activation
Wajsman et al. Further study of fibrinogen degradation products in bladder cancer detection
WO2001051660A3 (en) Method and kit for diagnosis of neoplastic transformation
US20170252020A1 (en) Fluid Sample Collection and Testing Method
EP1376133A4 (en) Method of screening prediabetic state and screening reagent
WO2007091033A1 (en) Portable kit and method for the estimation of time of death of a corpse by determining the hypoxanthine concentration in that corpse dependent on temperature and time
WO2005040754A3 (en) METHOD AND KIT FOR DETECTING LISTERIA spp.
EP0869362A3 (en) Quantitative determination method for heparan sulfate and diagnostic method using the same
WO2004093662A3 (en) Method for detecting prognosis of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP